A Louisiana judge paused the state's mifepristone lawsuit instead of ruling on it
Louisiana wanted mail and telehealth access to the drug shut down immediately. The judge denied that request but didn't dismiss the case either — he gave the FDA until October to finish its own review.
A federal court in the Western District of Louisiana ruled April 7 on Louisiana's lawsuit seeking to restrict mail and telehealth access to mifepristone — and neither side fully got what it wanted. The court denied Louisiana's request for "severe and immediate restrictions on mifepristone" that would have blocked mail and telemedicine prescribing nationwide, but it also declined to dismiss the case outright. Instead, it paused the litigation to let the Trump administration's FDA complete its own review of the drug, ordering the agency to report on the status of that review by October 7, 2026 [s1].
The case is State of Louisiana et al. v. Food and Drug Administration et al., filed in that court on October 6, 2025 [s2]. Louisiana did not accept the pause as a resolution — the litigation tracker shows plaintiffs filed a notice of appeal the very next day, April 8 [s2].
What the ruling does and doesn't do
The order accomplishes two things at once. It denies Louisiana's bid to immediately restrict how mifepristone can be prescribed and dispensed — the outcome reproductive-rights groups had been fighting to prevent — while also keeping the underlying lawsuit alive rather than throwing it out [s1]. That combination means the practical status quo continues for now: nothing in this order changes how mifepristone can currently be prescribed or dispensed.
But "paused, not dismissed" is also not a win for the FDA's regulatory position. The court did not rule that Louisiana's legal theory is wrong — it simply declined to grant relief while the agency finishes reviewing the drug on its own timeline, with a checkpoint report due in October. Whatever that FDA review concludes could reshape the legal landscape before the court ever has to resolve the underlying dispute.
Julia Kaye, senior staff attorney with the ACLU's Reproductive Freedom Project, characterized the order as a mixed outcome rather than a defeat for Louisiana's opponents: "Putting this baseless case on hold is certainly a better outcome than what Louisiana asked for," she said, while warning that the administration's review is "designed to manufacture an excuse for further restricting medication abortion across the nation" [s1].
A case with a short procedural history
Filed in October 2025, the case moved through motions to intervene, briefing on a preliminary injunction, and multiple rounds of amicus filings before the April 7 opinion [s2]. Two mifepristone manufacturers, GenBioPro and Danco Laboratories, filed notices as proposed intervenors within days of the original complaint, and both companies later moved to intervene formally and opposed Louisiana's request for preliminary relief [s2]. The FDA itself had asked the court back in January to pause proceedings, a request the April order effectively granted, if not on the government's exact terms [s2].
That the manufacturers of both the brand-name and generic versions of the drug intervened as defendants signals how directly a ruling favoring Louisiana would have affected their ability to distribute the product through the mail and telehealth channels the state's suit sought to close off.
Why the appeal matters more than the pause
A pause is, by design, not a final word. Louisiana's decision to appeal within a day signals the state does not intend to wait out the FDA's review or the court's chosen timeline. The case now heads to the U.S. Court of Appeals for the Fifth Circuit, which will first have to decide whether it can or should hear an appeal of an order that paused rather than resolved the case below — a threshold procedural question separate from the underlying dispute over mifepristone access.
What to watch
Two clocks are now running independently: the FDA's own review, due to be reported on by October 7, 2026, and whatever the Fifth Circuit decides to do with Louisiana's April 8 notice of appeal. Either could move faster than the other and change the practical stakes of the case well before the six-month window closes. Nothing in the April 7 order changes current mifepristone access; readers seeking guidance on medication abortion or miscarriage management should consult a clinician, as regulatory status can change with further litigation.
This article is informational and is not medical advice.
Sources
- [s1] American Civil Liberties Union, "Federal Court Pauses Case Seeking to Restrict Abortion and Miscarriage Medication," 7 April 2026. https://www.aclu.org/press-releases/federal-court-pauses-case-seeking-to-restrict-abortion-and-miscarriage-medication
- [s2] Georgetown University Health Care Litigation Tracker, "State of Louisiana et al. v. Food and Drug Administration et al.," accessed 8 April 2026. https://litigationtracker.law.georgetown.edu/litigation/state-of-louisiana-et-al-v-food-and-drug-administration-et-al/
Sources
- Federal Court Pauses Case Seeking to Restrict Abortion and Miscarriage Medication — American Civil Liberties Union , April 7, 2026
- State of Louisiana et al. v. Food and Drug Administration et al. — Litigation Tracker — Georgetown University Health Care Litigation Tracker , April 8, 2026
NIH moves to license a government-owned mifepristone dosing method to a French firm
The patented method uses mifepristone for hypercortisolism-related insulin resistance, with dosing capped to avoid over-activating the stress-hormone axis. The public can object before the deal closes.
A judge stayed the reconstituted CDC vaccine panel and its January schedule changes
Judge Brian Murphy found the government likely broke two federal laws when it bypassed ACIP and replaced its members. The ruling reverts the childhood schedule and cancels this week's ACIP meeting.
HHS declares grounds for emergency use of pain drugs for military casualties
A section 564 declaration, prompted by a July determination from the Secretary of War, opens the door to authorising unapproved drugs for acute pain in combat and CBRN casualties.
FDA rewrites its guidance on studying drug doses in liver-impaired patients
A draft replacing a 2003 document would extend hepatic-impairment dosing studies to biologic drugs and to drug effects, not just blood levels. It is open for comment before the agency finalises it.